NMDA receptor antagonists (NR2B subtype-selective) (Merck & Co)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameNMDA receptor antagonists (NR2B subtype-selective) (Merck & Co)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor subunit epsilon 2 antagonists
TargetsGlutamate [NMDA] receptor subunit epsilon 2
Therapy Area/IndicationsNeuralgiaEpilepsyStroke +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Research Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme Research Gmbh
Active IndicationsN/A
Inactive IndicationsNeuralgiaEpilepsyStroke +[4] 

Other Information

ATC CodeN/A
Related LinksN/A